Targeting ATR in cancer medicine
Sundar R, Brown J, Russo A, Yap T. Targeting ATR in cancer medicine. Current Problems In Cancer 2017, 41: 302-315. PMID: 28662958, DOI: 10.1016/j.currproblcancer.2017.05.002.Peer-Reviewed Original ResearchPoly(ADP-ribose) polymerase inhibitorsATR inhibitorsDNA damage responsePolymerase inhibitorsEarly-phase clinical trialsAtaxia telangiectasiaImmune checkpoint inhibitorsBiomarkers of responseCheckpoint inhibitorsDNA damagePreclinical dataCombinatorial regimensPatient selectionReplication-associated DNA damageAntitumor strategyCell cycle checkpoint signalingClinical developmentRepair of replication-associated DNA damagePreclinical biologyTargeting ATRAntitumor therapyATR inhibitionSingle agentCell cycle checkpointsClinical trialsCombining Molecularly Targeted Agents: Is More Always Better?
Sundar R, Valeri N, Harrington K, Yap T. Combining Molecularly Targeted Agents: Is More Always Better? Clinical Cancer Research 2017, 23: 1123-1125. PMID: 27836864, DOI: 10.1158/1078-0432.ccr-16-2399.Peer-Reviewed Original Research